Search

Your search keyword '"Khimani, Farhad"' showing total 575 results
Start Over Author "Khimani, Farhad"
575 results on '"Khimani, Farhad"'

1. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

Author

Shadman, Mazyar, Ahn, Kwang W., Kaur, Manmeet, Lekakis, Lazaros, Beitinjaneh, Amer, Iqbal, Madiha, Ahmed, Nausheen, Hill, Brian, Hossain, Nasheed M., Riedell, Peter, Gopal, Ajay K., Grover, Natalie, Frigault, Matthew, Brammer, Jonathan, Ghosh, Nilanjan, Merryman, Reid, Lazaryan, Aleksandr, Ram, Ron, Hertzberg, Mark, Savani, Bipin, Awan, Farrukh, Khimani, Farhad, Ahmed, Sairah, Kenkre, Vaishalee P., Ulrickson, Matthew, Shah, Nirav, Kharfan-Dabaja, Mohamed A., Herrera, Alex, Sauter, Craig, and Hamadani, Mehdi

Published
2024
Full Text
View/download PDF

3. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.

Author

Shaw, Bronwen, Jimenez-Jimenez, Antonio, Burns, Linda, Logan, Brent, Khimani, Farhad, Shaffer, Brian, Shah, Nirav, Mussetter, Alisha, Tang, Xiao-Ying, McCarty, John, Alavi, Asif, Farhadfar, Nosha, Jamieson, Katarzyna, Hardy, Nancy, Choe, Hannah, Ambinder, Richard, Anasetti, Claudio, Perales, Miguel-Angel, Spellman, Stephen, Howard, Alan, Luznik, Leo, Norkin, Maxim, Pidala, Joseph, Ratanatharathorn, Voravit, Confer, Dennis, Devine, Steven, Horowitz, Mary, Bolaños-Meade, Javier, and Komanduri, Krishna

Subjects
HLA, Hematopoietic cell transplant, Mismatched unrelated donor, Post transplant cyclophosphamide, Humans, Bone Marrow, Follow-Up Studies, Prospective Studies, Cyclophosphamide, Graft vs Host Disease, Unrelated Donors, Recurrence
Abstract

The use of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis has resulted in reductions in GVHD and improved outcomes in allogeneic hematopoietic cell transplantation (HCT) using HLA-mismatched related donors. We report the 3-year outcomes of the first multicenter prospective clinical trial using PTCy in the setting of mismatched unrelated donor (MMUD) bone marrow HCT. The study enrolled 80 patients, treated with either myeloablative conditioning (MAC; n = 40) or reduced-intensity conditioning (RIC; n = 40), with the primary endpoint of 1-year overall survival (OS). The median follow-up for this study was 34 months (range, 12 to 46 months) in the RIC group and 36 months (range, 18 to 49 months) in the MAC group. Three-year OS and nonrelapse mortality were 70% and 15%, respectively, in the RIC group and 62% and 10% in the MAC group. No GVHD was reported after 1 year. The incidence of relapse was 29% in the RIC group and 51% in the MAC group. OS did not differ based on HLA match grade (63% in the 7/8 strata and 71% in the 4 to 6/8 strata). These encouraging outcomes, which were sustained for 3 years post-HCT, support the continued exploration of MMUD HCT using a PTCy platform. Important future areas to address include relapse reduction and furthering our understanding of optimal donor selection based on HLA and non-HLA factors.

Published
2023

6. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study

Author

Lee, Dae Hyun, Chandrasekhar, Sanjay, Jain, Michael D., Mhaskar, Rahul, Reid, Kayla, Lee, Sae Bom, Corallo, Salvatore, Hidalgo-Vargas, Melanie J., Kumar, Abhishek, Chavez, Julio, Shah, Bijal, Lazaryan, Aleksandr, Khimani, Farhad, Nishihori, Taiga, Bachmeier, Christina, Faramand, Rawan, Fradley, Michael G., Jeong, Daniel, Oliveira, Guilherme H., Locke, Frederick L., Davila, Marco L, and Alomar, Mohammed

Published
2023
Full Text
View/download PDF

7. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.

Author

Menghrajani, Kamal, Gomez-Arteaga, Alexandra, Madero-Marroquin, Rafael, Zhang, Mei-Jie, Bo-Subait, Khalid, Sanchez, Jonathan, Wang, Hai-Lin, Aljurf, Mahmoud, Assal, Amer, Bacher, Vera, Badawy, Sherif, Bejanyan, Nelli, Bhatt, Vijaya, Bredeson, Christopher, Byrne, Michael, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Ciurea, Stefan, DeFilipp, Zachariah, Farhadfar, Nosha, Gadalla, Shahinaz, Gale, Robert, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael, Hashmi, Shahrukh, Hildebrandt, Gerhard, Kanakry, Christopher, Kansagra, Ankit, Khimani, Farhad, Krem, Maxwell, Lazarus, Hillard, Liu, Hongtao, Martino, Rodrigo, Michelis, Fotios, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard, Reshef, Ran, Rizzieri, David, Rowe, Jacob, Savani, Bipin, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Ustun, Celalettin, Verdonck, Leo, Hourigan, Christopher, Sandmaier, Brenda, Litzow, Mark, Kebriaei, Partow, Weisdorf, Daniel, Zhang, Yanming, Tallman, Martin, and Saber, Wael

Subjects
Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Recurrence, Remission Induction
Abstract

Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the CIBMTR database, and after selection and manual curation of the cytogenetics data, 3779 patients in first complete remission were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. An adjusted multivariable analysis detected an increased risk of relapse for patients with KMT2A-rearranged or adverse-risk AML as compared to those with intermediate-risk disease (hazards ratio [HR], 1.27; P = .01; HR, 1.71; P < .001, respectively). Leukemia-free survival was similar for patients with KMT2A rearrangement or adverse risk (HR, 1.26; P = .002, and HR, 1.47; P < .001), as was overall survival (HR, 1.32; P < .001, and HR, 1.45; P < .001). No differences in outcome were detected when patients were stratified by KMT2A fusion partner. This study is the largest conducted to date on post-HCT outcomes in AML, with manually curated cytogenetics used for risk stratification. Our work demonstrates that risk classification at diagnosis remains predictive of post-HCT outcomes in AML. It also highlights the critical need to develop novel treatment strategies for patients with KMT2A-rearranged and adverse-risk disease.

Published
2022

8. Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide

Author

Elmariah, Hany, Otoukesh, Salman, Kumar, Ambuj, Haris Ali, Shukaib Arslan, Dimaggio, Elizabeth, Gonzalez, Rebecca, Shouse, Geoffrey, Pourhassan, Hoda, Taiga Nishihori, Faramand, Rawan, Mishra, Asmita, Khimani, Farhad, Fernandez, Hugo, Lazaryan, Aleksandr, Nieder, Michael, Perez, Lia, Liu, Hien, Ryotaro Nakamura, Pidala, Joseph, Guido Marcucci, Stephen J Forman, Anasetti, Claudio, Bejanyan, Nelli, and Monzr M Al Malki

Published
2024
Full Text
View/download PDF

9. JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Author

Pidala, Joseph, Holtan, Shernan G., Walton, Kelly, Kim, Jongphil, Cao, Biwei, Elmariah, Hany, Mishra, Asmita, Bejanyan, Nelli, Nishihori, Taiga, Khimani, Farhad, Perez, Lia, Faramand, Rawan G., Davila, Marco L., McSain, Shannon, Pleskow, Jordan, Baron, Jeffrey, Anasetti, Claudio, Moran Segura, Carlos, Weisdorf, Daniel J., Blazar, Bruce R., Miller, Jeffrey S., Bachanova, Veronika, El Jurdi, Najla, and Betts, Brian C.

Published
2024
Full Text
View/download PDF

10. National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide

Author

Shaw, Bronwen E, Jimenez-Jimenez, Antonio Martin, Burns, Linda J, Logan, Brent R, Khimani, Farhad, Shaffer, Brian C, Shah, Nirav N, Mussetter, Alisha, Tang, Xiao-Ying, McCarty, John M, Alavi, Asif, Farhadfar, Nosha, Jamieson, Katarzyna, Hardy, Nancy M, Choe, Hannah, Ambinder, Richard F, Anasetti, Claudio, Perales, Miguel-Angel, Spellman, Stephen R, Howard, Alan, Komanduri, Krishna V, Luznik, Leo, Norkin, Maxim, Pidala, Joseph A, Ratanatharathorn, Voravit, Confer, Dennis L, Devine, Steven M, Horowitz, Mary M, and Bolaños-Meade, Javier

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Immunology, Transplantation, Clinical Trials and Supportive Activities, Hematology, Rare Diseases, Clinical Research, Regenerative Medicine, Good Health and Well Being, Adolescent, Adult, Aged, Cyclophosphamide, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Lymphoma, Male, Medically Underserved Area, Middle Aged, Minority Groups, Myelodysplastic Syndromes, Prospective Studies, Registries, Transplantation Conditioning, Unrelated Donors, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeHematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched unrelated donor, with significant disparity across ethnic groups. We hypothesized that HCT with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity using mismatched related donors, would be feasible and increase access to HCT.Patients and methodsWe performed a prospective phase II study of MMUD bone marrow HCT with PTCy for patients with hematologic malignancies. The primary end point was 1-year overall survival (OS), hypothesized to be 65% or better. 80 patients enrolled at 11 US transplant centers (December 2016-March 2019). Following myeloablative or reduced-intensity conditioning-based HCT, patients received PTCy on days +3, +4, with sirolimus and mycophenolate mofetil starting on day +5. We compared outcomes to Center for International Blood and Marrow Transplant Research contemporary controls receiving PTCy.ResultsNotably, 48% of patients enrolled were ethnic minorities. 39% of pairs were matched for 4-6 out of 8 HLA alleles. The primary end point was met, with 1-year OS of 76% (90% CI, 67.3 to 83.3) in the entire cohort, and 72% and 79% in the myeloablative and reduced-intensity conditioning strata, respectively. Secondary end points related to engraftment and graft-versus-host-disease were reached. Multivariate analysis comparing the study group with other mismatched HCT controls found no significant differences in OS.ConclusionOur prospective study demonstrates the feasibility and effectiveness of HCT with an MMUD in the setting of PTCy. Remarkably, nearly half of the study participants belonged to an ethnic minority population, suggesting this approach may significantly expand access to HCT.

Published
2021

11. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

Author

Lee, Dae Hyun, Kumar, Abhishek, Mohammed, Turab, Peres, Lauren C., Alsina, Melissa, Bachmeier, Christina, Blue, Brandon J., Brayer, Jason, Chandrasekhar, Sanjay, Grajales Cruz, Ariel, De Avila, Gabe, Elmariah, Hany, Faramand, Rawan, Freeman, Ciara, Jain, Michael, Khadka, Sushmita, Khimani, Farhad, Liu, Hien, Nishihori, Taiga, Oswald, Laura B., Castaneda Puglianini, Omar A., Shain, Kenneth H., Smith, Eric, Baz, Rachid C., Locke, Frederick L., Oliveira, Guilherme H., Alomar, Mohammed, and Hansen, Doris K.

Published
2023
Full Text
View/download PDF

12. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma

Author

Zhang, Yumeng, Rose, Ashley, Khadka, Sushmita, Cao, Biwei, Eatrides, Jennifer, Saeed, Hayder, Shah, Bijal D., Chavez, Julio, Bello, Celeste, Lazaryan, Aleksandr, Khimani, Farhad, Ibarz, Javier Pinilla, Liu, Hien D., Locke, Frederick L., Jain, Michael D., Zhang, Ling, Kharfan-Dabaja, Mohamed A., Kim, Jongphil, Ayala, Ernesto, Nishihori, Taiga, and Sokol, Lubomir

Published
2024
Full Text
View/download PDF

13. Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.

Author

Al Malki, Monzr M., primary, Bo-Subait, Stephanie, additional, Logan, Brent, additional, Olson, Janelle, additional, Leckrone, Erin, additional, Wu, Juan, additional, Stefanski, Heather E., additional, Auletta, Jeffery J., additional, Spellman, Stephen R., additional, Malmberg, Craig, additional, Shaffer, Brian C., additional, Modi, Dipenkumar, additional, Khimani, Farhad, additional, Gooptu, Mahasweta, additional, Hamadani, Mehdi, additional, Broglie, Larisa, additional, Shaw, Bronwen E., additional, Devine, Steven Michael, additional, and Jimenez Jimenez, Antonio Martin, additional

Published
2024
Full Text
View/download PDF

14. A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma

Author

Moustafa, Muhamad Alhaj, primary, Ramdial, Jeremy L., additional, Tsalatsanis, Athanasios, additional, Khimani, Farhad, additional, Dholaria, Bhagirathbhai, additional, Bojanini, Leyla, additional, Brooks, Taylor, additional, Zain, Jasmine, additional, Bennani, N. Nora, additional, Braunstein, Zachary, additional, Brammer, Jonathan E., additional, Beitinjaneh, Amer, additional, Jagadeesh, Deepa, additional, Weng, Wen Kai, additional, Kumar, Ambuj, additional, Kharfan-Dabaja, Mohamed A., additional, Ahmed, Sairah, additional, and Murthy, Hemant S., additional

Published
2024
Full Text
View/download PDF

15. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

Author

Logue, Jennifer M., Peres, Lauren C., Hashmi, Hamza, Colin-Leitzinger, Christelle M., Shrewsbury, Alexandria M., Hosoya, Hitomi, Gonzalez, Rebecca M., Copponex, Christina, Kottra, Krista H., Hovanky, Vanna, Sahaf, Bita, Patil, Sunita, Lazaryan, Aleksandr, Jain, Michael D., Baluch, Aliyah, Klinkova, Olga V., Bejanyan, Nelli, Faramand, Rawan G., Elmariah, Hany, Khimani, Farhad, Davila, Marco L., Mishra, Asmita, Blue, Brandon J., Grajales-Cruz, Ariel F., Castaneda Puglianini, Omar A., Liu, Hien D., Nishihori, Taiga, Freeman, Ciara L., Brayer, Jason B., Shain, Kenneth H., Baz, Rachid C., Locke, Frederick L., Alsina, Melissa, Sidana, Surbhi, and Hansen, Doris K.

Published
2022
Full Text
View/download PDF

16. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Author

Shadman, Mazyar, Pasquini, Marcelo, Ahn, Kwang Woo, Chen, Yue, Turtle, Cameron J., Hematti, Peiman, Cohen, Jonathon B., Khimani, Farhad, Ganguly, Siddhartha, Merryman, Reid W., Yared, Jean A., Locke, Frederick L., Ahmed, Nausheen, Munshi, Pashna N., Beitinjaneh, Amer, Reagan, Patrick M., Herrera, Alex F., Sauter, Craig S., Kharfan-Dabaja, Mohamed A., and Hamadani, Mehdi

Published
2022
Full Text
View/download PDF

17. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics

Author

Hamadani, Mehdi, Ngoya, Maud, Sureda, Anna, Bashir, Qaiser, Litovich, Carlos Alejandro, Finel, Hervé, Chen, Yue, Boumendil, Ariane, Zain, Jasmine, Castagna, Luca, Cashen, Amanda F., Blaise, Didier, Shadman, Mazyar, Pastano, Rocco, Khimani, Farhad, Arat, Mutlu, Dietrich, Sascha, Schmitz, Norbert, Glass, Bertram, Kharfan-Dabaja, Mohamed A., Corradini, Paolo, Sauter, Craig S., Montoto, Silvia, Kwon, Mi, Herrera, Alex F., and Dreger, Peter

Published
2022
Full Text
View/download PDF

18. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease

Author

Lazaryan, Aleksandr, Lee, Stephanie, Arora, Mukta, Kim, Jongphil, Betts, Brian Christopher, Khimani, Farhad, Nishihori, Taiga, Bejanyan, Nelli, Liu, Hien, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Gonzalez, Rebecca, Jain, Michael D., Davila, Marco L., Perez, Lia Elena, Mishra, Asmita, Perez Perez, Ariel, Balke, Karlie, Ayala, Ernesto, Ochoa, Leonel, Castaneda Puglianini, Omar, Faramand, Rawan, Alsina, Melissa, Elmariah, Hany, Nieder, Michael L., Fernandez, Hugo, Anasetti, Claudio, and Pidala, Joseph A.

Published
2022
Full Text
View/download PDF

19. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide

Author

Elmariah, Hany, Otoukesh, Salman, Kumar, Ambuj, Ali, Haris, Arslan, Shukaib, Shouse, Geoffrey, Pourhassan, Hoda, Nishihori, Taiga, Faramand, Rawan, Mishra, Asmita, Khimani, Farhad, Fernandez, Hugo, Lazaryan, Aleksandr, Nieder, Michael, Perez, Lia, Liu, Hien, Nakamura, Ryotaro, Pidala, Joseph, Marcucci, Guido, Forman, Stephen J., Anasetti, Claudio, Locke, Frederick, Bejanyan, Nelli, and Al Malki, Monzr M.

Published
2024
Full Text
View/download PDF

21. Mismatched donor allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations

Author

Caprice, Teresa, primary, Fan, Wenyi, additional, Kim, Jongphil, additional, Faramand, Rawan, additional, Mishra, Asmita, additional, Perez, Lia, additional, Khimani, Farhad, additional, Lazar‐yan, Aleksandr, additional, Ochoa‐Bayona, Jose L., additional, Liu, Hien, additional, Jain, Michael D., additional, Nieder, Michael, additional, Anasetti, Claudio, additional, Nishihori, Taiga, additional, Pidala, Joseph A., additional, Bejanyan, Nelli, additional, and Elmariah, Hany, additional

Published
2024
Full Text
View/download PDF

22. Table S5 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

Author

Faramand, Rawan G., primary, Lee, Sae Bom, primary, Jain, Michael D., primary, Cao, Biwei, primary, Wang, Xuefeng, primary, Rejeski, Kai, primary, Subklewe, Marion, primary, Fahrmann, Johannes F., primary, Saini, Neeraj Y., primary, Hanash, Samir M., primary, Kang, Yun Pyo, primary, Chang, Darwin, primary, Rodriguez, Paolo C., primary, Dean, Erin A., primary, Nishihori, Taiga, primary, Shah, Bijal D., primary, Lazaryan, Aleksandr, primary, Chavez, Julio, primary, Khimani, Farhad, primary, Pinilla-Ibarz, Javier A., primary, Dam, Marian, primary, Reid, Kayla M., primary, Corallo, Salvatore A., primary, Menges, Meghan, primary, Hidalgo Vargas, Melanie, primary, Mandula, Jay K., primary, Holliday, Brian A., primary, Bachmeier, Christina A., primary, Speth, Kelly, primary, Song, Qinghua, primary, Mattie, Mike, primary, Locke, Frederick L., primary, and Davila, Marco L., primary

Published
2024
Full Text
View/download PDF

23. Data from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

Author

Faramand, Rawan G., primary, Lee, Sae Bom, primary, Jain, Michael D., primary, Cao, Biwei, primary, Wang, Xuefeng, primary, Rejeski, Kai, primary, Subklewe, Marion, primary, Fahrmann, Johannes F., primary, Saini, Neeraj Y., primary, Hanash, Samir M., primary, Kang, Yun Pyo, primary, Chang, Darwin, primary, Rodriguez, Paolo C., primary, Dean, Erin A., primary, Nishihori, Taiga, primary, Shah, Bijal D., primary, Lazaryan, Aleksandr, primary, Chavez, Julio, primary, Khimani, Farhad, primary, Pinilla-Ibarz, Javier A., primary, Dam, Marian, primary, Reid, Kayla M., primary, Corallo, Salvatore A., primary, Menges, Meghan, primary, Hidalgo Vargas, Melanie, primary, Mandula, Jay K., primary, Holliday, Brian A., primary, Bachmeier, Christina A., primary, Speth, Kelly, primary, Song, Qinghua, primary, Mattie, Mike, primary, Locke, Frederick L., primary, and Davila, Marco L., primary

Published
2024
Full Text
View/download PDF

24. Figure S2 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

Author

Faramand, Rawan G., primary, Lee, Sae Bom, primary, Jain, Michael D., primary, Cao, Biwei, primary, Wang, Xuefeng, primary, Rejeski, Kai, primary, Subklewe, Marion, primary, Fahrmann, Johannes F., primary, Saini, Neeraj Y., primary, Hanash, Samir M., primary, Kang, Yun Pyo, primary, Chang, Darwin, primary, Rodriguez, Paolo C., primary, Dean, Erin A., primary, Nishihori, Taiga, primary, Shah, Bijal D., primary, Lazaryan, Aleksandr, primary, Chavez, Julio, primary, Khimani, Farhad, primary, Pinilla-Ibarz, Javier A., primary, Dam, Marian, primary, Reid, Kayla M., primary, Corallo, Salvatore A., primary, Menges, Meghan, primary, Hidalgo Vargas, Melanie, primary, Mandula, Jay K., primary, Holliday, Brian A., primary, Bachmeier, Christina A., primary, Speth, Kelly, primary, Song, Qinghua, primary, Mattie, Mike, primary, Locke, Frederick L., primary, and Davila, Marco L., primary

Published
2024
Full Text
View/download PDF

25. Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

Author

Faramand, Rawan G., primary, Lee, Sae Bom, additional, Jain, Michael D., additional, Cao, Biwei, additional, Wang, Xuefeng, additional, Rejeski, Kai, additional, Subklewe, Marion, additional, Fahrmann, Johannes F., additional, Saini, Neeraj Y., additional, Hanash, Samir M., additional, Kang, Yun Pyo, additional, Chang, Darwin, additional, Rodriguez, Paolo C., additional, Dean, Erin A., additional, Nishihori, Taiga, additional, Shah, Bijal D., additional, Lazaryan, Aleksandr, additional, Chavez, Julio, additional, Khimani, Farhad, additional, Pinilla-Ibarz, Javier A., additional, Dam, Marian, additional, Reid, Kayla M., additional, Corallo, Salvatore A., additional, Menges, Meghan, additional, Hidalgo Vargas, Melanie, additional, Mandula, Jay K., additional, Holliday, Brian A., additional, Bachmeier, Christina A., additional, Speth, Kelly, additional, Song, Qinghua, additional, Mattie, Mike, additional, Locke, Frederick L., additional, and Davila, Marco L., additional

Published
2024
Full Text
View/download PDF

27. JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Author

Pidala, Joseph A., primary, Holtan, Shernan Grace, additional, Walton, Kelly, additional, Kim, Jongphil, additional, Elmariah, Hany, additional, Mishra, Asmita, additional, Bejanyan, Nelli, additional, Nishihori, Taiga, additional, Khimani, Farhad, additional, Perez, Lia Elena, additional, Faramand, Rawan G, additional, Davila, Dr. Marco L., additional, Anasetti, Claudio, additional, Weisdorf, Daniel J., additional, Blazar, Bruce R., additional, Miller, Dr. Jeffrey S., additional, Bachanova, Veronika, additional, El Jurdi, Najla, additional, and Betts, Brian C., additional

Published
2024
Full Text
View/download PDF

28. Outcomes of Haploidentical Stem Cell Transplant Recipients with HHV-6 Reactivation Receiving Antiviral Therapy

Author

Yepes, Amanda, primary, Faramand, Rawan G, additional, Bejanyan, Nelli, additional, Nishihori, Taiga, additional, Locke, Frederick L., additional, Jain, Michael D., additional, Nieder, Dr. Michael L., additional, Elmariah, Hany, additional, Khimani, Farhad, additional, Liu, Hien, additional, Mishra, Asmita, additional, Perez, Lia Elena, additional, Alsina, Melissa, additional, Castaneda, Omar, additional, Hansen, Doris K, additional, Freeman, Ciara Louise, additional, Ochoa, Leonel, additional, Pidala, Joseph A., additional, Perna, Fabiana, additional, Mirza, Abu-Sayeef, additional, Eliassen, Eva, additional, Dominguez, Gabriel, additional, Lazaryan, Aleksandr, additional, Klinkova, Olga V, additional, Baluch, Aliyah, additional, Pasikhova, Dr. Yanina, additional, and Handley, Guy, additional

Published
2024
Full Text
View/download PDF

29. Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Acute Leukemia or MDS

Author

Auletta, Jeffery J., primary, Al Malki, Monzr M., additional, DeFor, Todd E., additional, Shaffer, Brian C., additional, Gooptu, Mahasweta, additional, Meade, Javier Bolaños, additional, Abboud, Ramzi, additional, Briggs, Adrienne, additional, Khimani, Farhad, additional, Modi, Dipenkumar, additional, Newcomb, Richard Andrew, additional, Shpall, Elizabeth J., additional, Bupp, Caitrin, additional, Spellman, Stephen R., additional, Stefanski, Dr. Heather E., additional, Jimenez Jimenez, Antonio M, additional, and Devine, Steven M., additional

Published
2024
Full Text
View/download PDF

30. Phase II Trial of Reduced-Intensity Fludarabine, Melphalan 70 Mg/m2, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Author

Elmariah, Hany, primary, Kim, Jongphil, additional, DiMaggio, Elizabeth, additional, Gonzalez, Rebecca, additional, Mishra, Asmita, additional, Faramand, Rawan G, additional, Perez, Lia Elena, additional, Lazaryan, Aleksandr, additional, Khimani, Farhad, additional, Liu, Hien, additional, Ochoa, Leonel, additional, Nieder, Dr. Michael L., additional, Figura, Nicholas, additional, Robinson, Timothy, additional, Nishihori, Taiga, additional, Anasetti, Claudio, additional, Pidala, Joseph A., additional, and Bejanyan, Nelli, additional

Published
2024
Full Text
View/download PDF

31. Expanded Antigen-Specific Donor Regulatory T Cells for Gvhd Prevention

Author

Pidala, Joseph A., primary, Betts, Brian C., additional, Schell, Michael, additional, Cao, Biwei, additional, Thapa, Ram, additional, Alsina, Melissa, additional, Bejanyan, Nelli, additional, Castaneda, Omar, additional, Elmariah, Hany, additional, Faramand, Rawan G, additional, Freeman, Ciara Louise, additional, Hansen, Doris K, additional, Jain, Michael D., additional, Khimani, Farhad, additional, Lazaryan, Aleksandr, additional, Liu, Hien, additional, Locke, Frederick L., additional, Mirza, Abu-Sayeef, additional, Mishra, Asmita, additional, Nieder, Dr. Michael L., additional, Nishihori, Taiga, additional, Ochoa, Leonel, additional, Perez, Lia Elena, additional, Perna, Fabiana, additional, and Anasetti, Claudio, additional

Published
2024
Full Text
View/download PDF

32. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation

Author

Khimani, Farhad, Ranspach, Peter, Elmariah, Hany, Kim, Jongphil, Whiting, Junmin, Nishihori, Taiga, Locke, Frederick L., Perez Perez, Ariel, Dean, Erin, Mishra, Asmita, Perez, Lia, Lazaryan, Aleksandr, Jain, Michael D., Nieder, Michael, Liu, Hein, Faramand, Rawan, Hansen, Doris, Alsina, Melissa, Ochoa, Leonel, Davila, Marco, Anasetti, Claudio, Pidala, Joseph, and Bejanyan, Nelli

Published
2021
Full Text
View/download PDF

35. Abstract 10475: Serial Inflammatory Cytokine Levels Are Increased in Atrial Fibrillation After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Author

Lee, Dae H, Jain, Michael, Faramand, Rawan G, Reid, Kayla, Lee, Sae Bom, Corallo, Salvatore, Hidalgo-Vargas, Melanie, Kumar, Abhishek, Chandrasekhar, Sanjay, Chavez, Julio, Shah, Bijal, Lazaryan, Aleksandr, Khimani, Farhad, Nishihori, Taiga, Bachmeier, Christina, Locke, Frederick, Oliveira, Guilherme, Alomar, Mohammed, and Davila, Marco L

Published
2022
Full Text
View/download PDF

36. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation

Author

Bejanyan, Nelli, Pidala, Joseph A., Wang, Xuefeng, Thapa, Ram, Nishihori, Taiga, Elmariah, Hany, Lazaryan, Aleksandr, Khimani, Farhad, Davila, Marco L., Mishra, Asmita, Faramand, Rawan, Jain, Michael D., Ochoa, Leonel, Perez, Lia Elena, Liu, Hien, Alsina, Melissa, Kharfan-Dabaja, Mohamed A., Fernandez, Hugo, Nieder, Michael L., Locke, Frederick L., Anasetti, Claudio, and Ayala, Ernesto

Published
2021
Full Text
View/download PDF

40. Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide

Author

Elmariah, Hany, primary, Otoukesh, Salman, additional, Kumar, Ambuj, additional, Ali, Haris, additional, Arslan, Shukaib, additional, Shouse, Geoffrey, additional, Pourhassan, Hoda, additional, Nishihori, Taiga, additional, Faramand, Rawan, additional, Mishra, Asmita, additional, Khimani, Farhad, additional, Fernandez, Hugo, additional, Lazaryan, Aleksandr, additional, Nieder, Michael, additional, Perez, Lia, additional, Liu, Hien, additional, Nakamura, Ryotaro, additional, Pidala, Joseph, additional, Marcucci, Guido, additional, Forman, Stephen J, additional, Anasetti, Claudio, additional, Locke, Frederick, additional, Bejanyan, Nelli, additional, and Al Malki, Monzr M, additional

Published
2023
Full Text
View/download PDF

43. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis

Author

Wood, Anthony C., Perez, Ariel Perez, Arciola, Brian, Patel, Kedar, Johnson, Grace, DiMaggio, Elizabeth, Bachmeier, Christina A., Reid, Kayla, Carallo, Salvatore, Vargas, Melanie H., Faramand, Rawan, Chavez, Julio C., Shah, Bijal, Gaballa, Sameh, Khimani, Farhad, Elmariah, Hany, Nishihori, Taiga, Lazaryan, Aleksandr, Freeman, Ciara, Davila, Marco L., Locke, Frederick L., Mhaskar, Rahul, Bassil, Claude, and Jain, Michael D.

Published
2022
Full Text
View/download PDF

44. MM-059 Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Mohammed, Turab, primary, Peres, Lauren, additional, Colinleitzinger, Christelle, additional, Puglianini, Omar Castaneda, additional, Oswald, Laura, additional, de Avila, Gabe, additional, Grajales-Cruz, Ariel, additional, Blue, Brandon, additional, Ochoa-Bayona, Jose, additional, Khimani, Farhad, additional, Faramand, Rawan, additional, Elmariah, Hany, additional, Lazaryan, Aleksandr, additional, Jain, Michael, additional, Liu, Hein, additional, Nishihori, Taiga, additional, Shain, Ken, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Locke, Frederick, additional, Freeman, Ciara, additional, and Hansen, Doris, additional

Published
2023
Full Text
View/download PDF

45. POSTER: MM-059 Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Mohammed, Turab, primary, Peres, Lauren, additional, Colinleitzinger, Christelle, additional, Puglianini, Omar Castaneda, additional, Oswald, Laura, additional, de Avila, Gabe, additional, Grajales-Cruz, Ariel, additional, Blue, Brandon, additional, Ochoa-Bayona, Jose, additional, Khimani, Farhad, additional, Faramand, Rawan, additional, Elmariah, Hany, additional, Lazaryan, Aleksandr, additional, Jain, Michael, additional, Liu, Hein, additional, Nishihori, Taiga, additional, Shain, Ken, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Locke, Frederick, additional, Freeman, Ciara, additional, and Hansen, Doris, additional

Published
2023
Full Text
View/download PDF

46. P1540: COVID-19 INFECTION AMONG CAR-T CELL THERAPY RECIPIENTS: A SINGLE CENTER EXPERIENCE

Author

Din, Mohammad Ammad Ud, primary, Oh, Nayeon, additional, Baluch, Aliyah, additional, Klinkova, Olga, additional, Quilitz, Rod, additional, Alsina, Melissa, additional, Bejanyan, Nelli, additional, Castaneda, Omar, additional, Chavez, Julio, additional, Elmariah, Hany, additional, Freeman, Ciara, additional, Hansen, Doris, additional, Jain, Michael, additional, Khimani, Farhad, additional, Lazaryan, Aleksandr, additional, Liu, Hien, additional, Mishra, Asmita, additional, Ochoa, Leonel, additional, Perez, Lia, additional, Pidala, Joseph, additional, Shah, Bijal, additional, Nishihori, Taiga, additional, Locke, Frederick, additional, and Faramand, Rawan, additional

Published
2023
Full Text
View/download PDF

47. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation

Author

Mirza, Abu-Sayeef, Tandon, Ankita, Jenneman, Dakota, Cao, Shu, Brimer, Thomas, Kumar, Ambuj, Kidd, Michelle, Khimani, Farhad, Faramand, Rawan, Mishra, Asmita, Liu, Hien, Nishihori, Taiga, Perez, Lia, Lazaryan, Aleksandr, Bejanyan, Nelli, Nieder, Michael, Anasetti, Claudio, Pidala, Joseph, and Elmariah, Hany

Published
2022
Full Text
View/download PDF

48. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study

Author

Murthy, Hemant S., Sheets, Kyle, Kumar, Ambuj, Nishihori, Taiga, Mina, Alain, Chavez, Julio C., Ayala, Ernesto, Field, Teresa, Mathews, John, Locke, Frederick, Perez, Lia, Betts, Brian C., Khimani, Farhad, Miladinovic, Branco, Tsalatsanis, Athanasios, Ochoa-Bayona, Jose Leonel, Alsina, Melissa, Fernandez, Hugo, Pidala, Joseph, Anasetti, Claudio, and Kharfan-Dabaja, Mohamed A.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results